Catalent, Inc.
CTLTHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $4.38B | $4.26B | $4.80B | $4.00B | $3.09B | $2.52B |
| Operating income | −$749.0M | −$163.0M | $730.0M | $828.0M | $394.0M | $274.0M |
| Net income | −$1.04B | −$256.0M | $499.0M | $585.0M | $221.0M | $137.0M |
| Total assets | $9.75B | $10.78B | $10.51B | $9.11B | $7.78B | $6.18B |
| Total liabilities | $6.15B | $6.17B | $5.73B | $4.84B | $4.27B | $3.90B |
| Equity | $3.60B | $4.61B | $4.78B | $3.92B | $2.90B | $1.68B |
| EPS (diluted) | $-5.76 | $-1.42 | $2.73 | $3.11 | $1.14 | $0.90 |
| Shares out. | 181.5M | 180.6M | 179.9M | 170.8M | 164.1M | 146.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −17.1%
- Net margin
- −23.8%
- Return on equity
- −28.9%
- Return on assets
- −10.7%
- Return on capital (ROCE)
- −8.6%
- Liabilities / assets
- 63.0%
- Debt / equity
- 1.71×
- Book value / share
- $19.86
- Revenue growth (YoY)
- 2.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- 0.89distress
- Accruals / assets
- −13.4%clean
- Beneish M-Score
- -3.23normal
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 2 warning● 3 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Aug 30, 2024
- NT 10-Qmissed a reporting deadline ↗Feb 12, 2024
- NT 10-Qmissed a reporting deadline ↗Nov 13, 2023
- NT 10-Kmissed a reporting deadline ↗Aug 30, 2023
- NT 10-Qmissed a reporting deadline ↗May 11, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
FDA-approved drugs
openFDA · most recent- CETIRIZINE HYDROCHLORIDE ALLERGYSep 21, 2020
- NAPROXEN SODIUMJan 4, 2019
- VALPROIC ACIDOct 29, 1991
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventDec 18, 2024
- Other material eventDec 16, 2024
- Other material eventDec 6, 2024
- Results of operationsNov 5, 2024
- Other material eventOct 21, 2024
- Results of operationsAug 29, 2024
- Director / officer change · Shareholder vote · Other material eventMay 29, 2024
- Other material eventMay 16, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.